A
T
P
About
Team
Portfolio
ATP R&D
News
Locations
Contact
Filter by
Year
All
2022
2021
2020
Archive
All
Company
All
ATP
Adendra Therapeutics
Akero Therapeutics
Aulos Bioscience
Braeburn
Gala Therapeutics
Galaxy Medical
Intergalactic Therapeutics
Marengo Therapeutics
Nereid Therapeutics
Nine Square Therapeutics
Replicate Bioscience
Stoke Therapeutics
Syntimmune
All
Aug 08, 2022
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Aug 01, 2022
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic
Jul 26, 2022
Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines
Jul 12, 2022
Replicate Bioscience Expands Leadership Team, Appointing Zelanna Goldberg, M.D., as Chief Medical Officer and Mohit Trikha, Ph.D., to Board of Directors
Jul 12, 2022
Marengo Therapeutics Announces Formation of Scientific Advisory Board to Advance the Company's Development of Novel Therapeutics for Precision Immuno-Oncology
Jun 16, 2022
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
Jun 15, 2022
Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer
Jun 09, 2022
Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)
May 26, 2022
Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting
May 10, 2022
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 09, 2022
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
May 05, 2022
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors
May 02, 2022
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002
Apr 27, 2022
Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting
Mar 21, 2022
Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors
Mar 10, 2022
Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Mar 09, 2022
Marengo Therapeutics to Participate in Investor, Scientific, Industry Conferences
Mar 07, 2022
Apple Tree Partners Donates to Humanitarian Relief Efforts in Ukraine
Mar 03, 2022
ATP Statement on War in Ukraine
Feb 23, 2022
Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007
Feb 08, 2022
Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx® System for Chronic Bronchitis
Jan 20, 2022
Intergalactic Therapeutics Announces Scientific Advisory Board Membership
Jan 11, 2022
Nine Square Therapeutics Appoints Robert Paul as CEO
Jan 10, 2022
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
Jan 06, 2022
Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference
Dec 07, 2021
ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series A
Dec 03, 2021
Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting
Nov 12, 2021
Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 08, 2021
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Nov 01, 2021
Nereid Therapeutics Announces Scientific Advisory Board Membership
Oct 25, 2021
Nereid Therapeutics Announces Appointments of Laura Forese and Rupert Vessey to Its Board of Directors
Oct 21, 2021
ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology
Oct 19, 2021
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
Oct 07, 2021
ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding
Oct 05, 2021
Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 04, 2021
ATP Founds New Center for CRISPR Target Discovery in Collaboration with Innovative Genomics Institute (IGI) and Jennifer Doudna
Sep 21, 2021
Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome
Sep 20, 2021
Galaxy Medical Enrolls First Patients in SPACE-AF Study
Sep 08, 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Aug 31, 2021
Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx™ System for Chronic Bronchitis
Jul 28, 2021
Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability
Jun 26, 2021
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Jun 15, 2021
Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Jun 14, 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
May 25, 2021
RNA: From the Messenger to the Medicine (Endpoints News Biotech Voices editorial by Stoke CEO Ed Kaye)
May 20, 2021
Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis
May 17, 2021
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
May 14, 2021
Nine Square: Taking Aim at Organelle Function in Movement Disorders with Computation and Imaging (BioCentury Emerging Company Profile)
May 12, 2021
Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter
May 08, 2021
Breathing Life into Britain’s Life-Sciences Industry (The Economist)
May 04, 2021
Stoke Presents New Data That Demonstrate Tango Antisense Oligonucleotides Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy
Mar 30, 2021
Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors
Mar 30, 2021
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom
Mar 22, 2021
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
Mar 16, 2021
Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias
Mar 15, 2021
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Mar 02, 2021
Doug Godshall to Chair Gala Therapeutics Board of Directors
Feb 22, 2021
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis
Jan 08, 2021
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
Dec 07, 2020
ATP Forms ATP V With $1 Billion in New Capital Commitments
Nov 24, 2020
Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nov 16, 2020
Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field
Oct 08, 2020
First Patients Treated with Galaxy Medical’s CENTAURI™ Pulsed Electric Field Cardiac Ablation System
Sep 09, 2020
Gala Therapeutics’ RheOx™ System Showcased at Virtual European Respiratory Society Congress
Sep 03, 2020
Results Published from Multicenter Study of Gala Therapeutics' Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis
Aug 26, 2020
Preclinical Data on Stoke Therapeutics' STK-001 Published in Science Translational Medicine
Aug 12, 2020
Four Questions for Neurology Startups as Venture Investors Pour Millions into the Field (STAT News)
Jul 10, 2020
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Jul 01, 2020
Apple Tree Partners Founds Nine Square Therapeutics to Pioneer Novel Treatments for Movement Disorders
Jun 12, 2020
Apple Tree Partners Portfolio Company Corvidia Therapeutics to be Acquired by Novo Nordisk
Jun 01, 2020
Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Sep 16, 2019
Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx™ System for Chronic Bronchitis
Sep 04, 2019
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx™ System for Chronic Bronchitis
Aug 06, 2019
Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome
Jul 23, 2019
U.S. District Court Orders FDA to Reconsider Application for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Jun 24, 2019
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Jun 21, 2019
Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jun 04, 2019
Braeburn Announces Publication of Phase 3 Study Results Showing Long-term Safety and Effectiveness of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Nov 02, 2018
Alexion Completes Acquisition Of Syntimmune
No articles match your selection. Try again.